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Abstract
The signaling mediated by the chemokine receptor CXC chemokine receptor 2 (CXCR2) plays an important role in
promoting the progression of many cancers, including pancreatic cancer, one of the most lethal human malignan-
cies. CXCR2 possesses a consensus PSD-95/DlgA/ZO-1 (PDZ) motif at its carboxyl termini, which might interact
with potential PDZ scaffold/adaptor proteins. We have previously reported that CXCR2 PDZ motif–mediated pro-
tein interaction is an important regulator for neutrophil functions. Here, using a series of biochemical assays, we
demonstrate that CXCR2 is physically coupled to its downstream effector phospholipase C–β3 (PLC-β3) that is
mediated by PDZ scaffold protein Na+/H+ exchange regulatory factor 1 (NHERF1) into a macromolecular signaling
complex both in vitro and in pancreatic cancer cells. We also observe that disrupting the CXCR2 complex, by gene
delivery or peptide delivery of exogenous CXCR2 C-tail, significantly inhibits the biologic functions of pancreatic
cancer cells (i.e., proliferation and invasion) in a PDZ motif–dependent manner. In addition, using a human pancre-
atic tumor xenograft model, we show that gene delivery of CXCR2 C-tail sequence (containing the PDZ motif) by
adeno-associated virus type 2 viral vector potently suppresses human pancreatic tumor growth in immunodeficient
mice. In summary, our results suggest the existence of a physical and functional coupling of CXCR2 and PLC-β3
mediated through NHERF1, forming a macromolecular complex that is critical for efficient and specific CXCR2
signaling in pancreatic cancer progression. Disrupting this CXCR2 complex could represent a novel and effective
treatment strategy against pancreatic cancer.
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Introduction
Pancreatic cancer, the most lethal malignancy of the gastrointestinal
tract with 5-year survival rates of less than 5%, is the fourth leading
cause of cancer-related deaths in both men and women in the United
States [1]. The most common type of pancreatic cancer is pancreatic
ductal adenocarcinoma (PDAC). Chemoresistance, early metastases,
and late clinical presentation in this incurable human malignancy result
in no effective methods for early prognosis as well as a lack of effective
systemic therapies with reduced side effects [2,3]. Therefore, a more
comprehensive understanding of PDAC biology and the mechanisms/
factors that promote tumor growth and metastasis may help identify
new molecular targets for the development of diagnostics and/or
therapeutics of pancreatic cancer.
CXC chemokine receptor 2 (CXCR2) is the cognate receptor for
the CXC chemokines CXCL1 to CXCL3 and CXCL5 to CXCL8
[4]. The CXC chemokine/CXCR2 signaling has been reported to
promote malignant cancer progression in many cancer types includ-
ing pancreatic cancer [5–9]. It has been documented that the elevated
expression of CXCL5 and CXCL8 is correlated with poor differen-
tiation, histopathologic grade, and advanced clinical grade pancreatic
adenocarcinomas in patients [10,11]. Recent studies also suggest that
CXCR2 is expressed in various PDAC cell lines [12–15] and is pri-
marily involved in enhancing the proliferation and survival of cancer
cells through the autocrine and/or paracrine effect [11,12,15]. More
importantly, increased expression of CXCR2 and its ligands has been
shown in higher grades and stages of pancreatic adenocarcinomas in
patients [10,16], indicating that CXCR2 is involved in the exacerba-
tion of tumors and could be a promising target for developing selective
and effective treatments for pancreatic cancer. As a G protein–coupled
receptor (GPCR), CXCR2 couples to the pertussis toxin–sensitive Gi
proteins to stimulate phosphatidylinositide-specific phospholipase C
(PLC) activities [17]. Agonist-induced activation of PLC-β, one of
the six families of PLC isozymes, catalyzes the hydrolysis of phosphati-
dylinositol 4,5-bisphosphate, generating 1,2-diacylglycerol and inositol
1,4,5-trisphosphate, which activates protein kinase C (PKC) isoforms
and triggers the release of Ca2+ from internal sources, respectively.
PSD-95/DlgA/ZO-1 (PDZ) domains are ubiquitous protein-protein
recognition modules that form peptide-binding pockets and generally
mediate physical interaction with the carboxyl termini of a wide variety
of proteins (such as membrane receptors, ion channel, and so on) that
terminate in consensus binding motifs (referred to as PDZ motif)
[18,19]. A variety of PDZ domain–containing proteins (also referred
to as PDZ scaffold/adaptor proteins) have been reported to nucleate
the formation of compartmentalized multiprotein complexes that
are critical for efficient and specific cell signaling [20–24]. Some
PDZ scaffold proteins, such as Na+/H+ exchange regulatory factor 1
(NHERF1) and NHERF2 and PDZ domain containing 1 (PDZK1),
preferentially associate with the surface membranes of epithelial cells
and interact with membrane receptors and their downstream effectors.
PLC-β is one of the downstream effectors for GPCR signaling, and it
has been reported to specifically bind with certain PDZ scaffold pro-
teins through PDZ-based interaction since all PLC-β isoforms possess
consensus PDZ motifs, -X-S/T-X-L/V-COOH (X represents any amino
acid), at their carboxyl termini [25–28]. Therefore, the specificity of
agonist-induced PLC-β activation and subsequent intracellular signal-
ing might be dependent on the specific interactions of PLC-β with
particular PDZ scaffold proteins [29]. Similar to PLC-β isoforms,
CXCR2 also possesses a consensus PDZ motif (-S-T-T-L-COOH) at
its carboxyl termini. Previous studies by us and others have demon-
strated that the PDZ motif of CXCR2 is involved in the regulation
of intracellular signaling and cell functions in neutrophils [30] as
well as post-endocytic sorting and cellular chemotaxis in CXCR2-
overexpressing human embryonic kidney 293 (HEK293) cells [31].
Hence, the PDZ motif of CXCR2 can, theoretically, mediate potential
interaction with certain PDZ scaffold proteins, which subsequently
binds relevant downstream effectors, forming multiprotein macro-
molecular complexes. However, the molecular mechanism(s) as to how
this potential CXCR2 macromolecular complex are formed and/or reg-
ulated, as well as what role the CXCR2 complex might play in PDAC
growth and progression, have not been determined.
In our present work, we applied a series of biochemical assays and
cell functional studies, as well as human PDAC xenograft animal
model, to explore the molecular mechanisms and functional signifi-
cance of the PDZ-based CXCR2 macromolecular complex in pan-
creatic tumor growth. Our data show that PDZ scaffold protein
NHERF1 clusters CXCR2 and its downstream effector enzyme
PLC-β3 into a macromolecular complex in PDAC cells. Moreover,
we demonstrated that disrupting the CXCR2–NHERF1–PLC-β3
macromolecular complex significantly inhibited malignant progres-
sion of pancreatic tumor in vitro and in vivo. Our results suggest that
targeting CXCR2 macromolecular complex may be a novel and effec-
tive therapeutic strategy for pancreatic cancer.
Materials and Methods
Antibodies and Reagents
Anti-human CXCR2, NHERF1, PLC-β3, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human
chemokines, CXCL8/IL-8, CXCL5/ENA-78, andCXCL1/GROα, were
obtained from ProSpec (East Brunswick, NJ). 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from
Sigma (St Louis, MO). Growth factor–reduced Matrigel matrix,
glutathione agarose beads, and Transwell inserts were purchased
from BD Biosciences (San Jose, CA). Human CXCR2 C-tail peptides
(biotin-conjugate at N terminus), wild-type “WT” (biotin-FVGSSSG-
HTSTTL), PDZ motif deletion mutant “ΔTTL” (biotin-FVGSSSG-
HTS), and PDZ motif mutant “AAA” (biotin-FVGSSSGHTSAAA),
were synthesized by Genemed Synthesis, Inc (San Antonio, TX) and
used as reported before [30]. Chariot peptide/protein delivery reagent
was purchased from Active Motif (Carlsbad, CA). S-protein agarose
and streptavidin beads were purchased from Novagen/EMD Millipore
(Billerica, MA). The plasmid pcDNA3.1(+)–FLAG–PLC-β3 used for
construct generation was described before [32].
Plasmid Construction, Mutagenesis, and Protein Purification
C-terminal tail fragments of human CXCR2 (last 45 amino acids;
i.e., amino acids 316–360) or human PLC-β3 (last 100 amino acids;
i.e., amino acids 1135–1234) were generated by polymerase chain
reaction cloning into pTriEx4 (encoding a His-S double tags at
N terminus) or pET30 (His-S tag; Novagen). Various C-tail PDZmotif
mutants (PDZmotif deletion ormutation) for either CXCR2 or PLC-β3
were generated using the QuikChange Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA) and also cloned into pTriEx4
or pET30 vectors for plasmid construction and protein purification.
Glutathione S-transferase (GST) PDZ fusion proteins (GST-NHERF1,
NHERF2, or PDZK1) were purified by using glutathione agarose beads
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(BD Biosciences) and eluted with 50 mM glutathione. His-S–tagged
fusion proteins for CXCR2C-tail or PLC-β3C-tail fragments (wild-type
and PDZ mutants) were purified using Cobalt resin (Thermo Scientific,
Hennigsdorf, Germany) and eluted with 200 mM imidazole. These
affinity-purified fusion proteins (full length and/or C-terminal tail frag-
ments) were used in the subsequent biochemical assays (such as pull-
down, pairwise binding, and macromolecular complex assembly).
Cell Culture and Transfection
Human PDAC cell lines (PANC-1, MIA PaCa-2, and HPAC) were
obtained from American Type Culture Collection (Manassas, VA).
Normal human pancreatic duct epithelial (HPDE) cells, Colo357
and L3.6pl cells were obtained from Dr Paul J Chiao at the University
of Texas MD Anderson Cancer Center (Houston, TX). PDAC cells
were cultured in Dulbecco’s modified Eagle’s medium (Thermo
Scientific Hyclone) containing 4.5 g/l D-glucose and L-glutamine sup-
plemented with 10% FBS, 100 units/ml penicillin, and 100 μg/ml
streptomycin at 37°C in humidified air with 5% CO2. HPDE cells
were cultured in keratinocyte serum-free medium (Invitrogen/Life
Technologies, Carlsbad, CA) supplied with 5 ng/ml epidermal growth
factor and 50 μg/ml bovine pituitary extract. In some experiments, cells
were cultured or incubated in serum-free or antibiotic-free media
wherever indicated. The PDAC cells were transfected with plasmids
encoding CXCR2 C-tail fragments (WT, PDZ motif deletion ΔTTL,
or PDZ motif mutation AAA) using Lipofectamine 2000 (Invitrogen/
Life Technologies) according to the manufacturer’s instructions. After
transfection, the PDAC cells were used for proliferation assays and
invasion assays.
Western Blot Analysis
Cells were lysed in lysis buffer [50mMTris (pH8.0), 150mMNaCl,
1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl
sulfate (SDS)] supplemented with a mixture of protease inhibitors (con-
taining 1mMphenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml
pepstatin, and 1 μg/ml leupeptin). Protein concentration of the cleared
supernatant (17,000g, 15 minutes) was estimated by Bradford protein
assay (Bio-Rad Laboratories, Redmond, WA). Proteins were eluted in
Laemmli sample buffer containing β-mercaptoethanol, separated by
SDS–polyacrylamide gel electrophoresis (PAGE; 7.5% or 4–15%),
and immunoblotted using indicated antibodies. The blots were visual-
ized and recorded using a BioSpectrum 500 Imaging System (UVP,
Upland, CA).
Pull-down Assay
GST pull-down assay was performed as previously described [30].
Briefly, fresh PDAC cells were lysed in binding buffer [phosphate-
buffered saline (PBS) + 0.2% Triton X-100, supplemented with a
mixture of protease inhibitors], and the cleared supernatant (17,000g,
15 minutes) was equally mixed with GST alone or various GST-PDZ
fusion proteins (GST-NHERF1, GST-NHERF2, or GST-PDZK1) at
4°C for 2 hours. The mixture was pulled down by glutathione agarose
beads at 4°C overnight, washed three times with binding buffer, and
eluted in Laemmli sample buffer containing β-mercaptoethanol. The
eluents were separated by SDS-PAGE and immunoblotted with anti-
CXCR2 or anti–PLC-β3 antibodies.
Pairwise Binding Assay
Purified GST-NHERF1 was mixed with various purified His-S–
PLC-β3C-tail fragments (WTor PDZmotif mutantsΔTQL and AAA)
or CXCR2 C-tail peptides (biotin-conjugate at N terminus; WT or
PDZ motif mutants ΔTTL and AAA) in binding buffer (PBS + 0.2%
Triton X-100 + protease inhibitors) at 22 to 24°C for 1 hour. The
mixtures were incubated with S-protein agarose (for His-S–tagged
fusion proteins) or streptavidin beads (for biotin-conjugated peptides)
for 2 hours. The beads were washed three times with binding buffer
and eluted with Laemmli sample buffer containing β-mercaptoethanol.
The eluents were resolved by SDS-PAGE and immunoblotted with
anti-NHERF1 antibody.
Macromolecular Complex Assembly
Purified His-S–tagged CXCR2 C-tail fragments (WT and PDZ
motif mutants ΔTTL or AAA) or His-S–tagged PLC-β3 C-tail frag-
ments (WT and PDZ motif mutants ΔTQL or AAA) were mixed
with GST-NHERF1 (or GST alone) in 200 μl of binding buffer
(PBS + 0.2% Triton X-100 + protease inhibitors), and the complex
was pulled down with S-protein agarose. This step is also referred to
as pairwise binding as described above. The dimeric complex was
then mixed with the lysates of PDAC cells expressing endogenous
full-length PLC-β3 and CXCR2 for 3 hours at 4°C and washed
extensively with binding buffer. The bound proteins were then eluted
and immunoblotted using anti–PLC-β3 or anti-CXCR2 antibodies.
Co-immunoprecipitation
A Co-immunoprecipitation Kit (Thermo Scientific/Pierce) was
used to immobilize the normal IgG control and anti-CXCR2 IgG
to the resin according to the manufacturer’s instruction. PDAC cells
were lysed in binding buffer (PBS + 0.2% Triton X-100 + protease
inhibitors), and cleared cell lysates (17,000g, 15 minutes) were pro-
cessed for co-immunoprecipitation (co-IP) as reported before [22,30].
The co-precipitated protein complex was resolved by SDS-PAGE and
probed for NHERF1 and PLC-β3. For the reverse co-IP, anti–PLC-β3
IgG was used to immunoprecipitate the complex. The co-precipitated
protein complexwas separated by SDS-PAGE and probed forNHERF1
and CXCR2. The signal was detected by SuperSignal West Pico (or
Femto) substrate (Thermo Scientific).
Cell Proliferation Assay
Cell proliferation was assessed by MTT assay as reported before
[11]. In brief, PDAC cells were seeded in 96-well plates (7 × 103 cells
per well) and allowed to adhere overnight. Then, the cells were fed with
serum-free fresh media with or without 100 ng/ml CXCR2 ligands
(CXCL1, CXCL5, or CXCL8). After indicated growth periods, cells
were incubated with 20 μl of MTT solution (1 mg/ml) at 37°C for
3.5 hours and then incubated with MTT solvent (4 mM HCl, 0.1%
NP-40 in isopropanol) under constant mixing protected from light for
15 minutes at 22 to 24°C. Spectrophotometric absorbance of the
samples at 590 nm was determined by a microplate reader (Bio-Rad).
In parallel, Colo357 and HPAC cells were transfected with various
pTriEx4 plasmids (vector alone, CXCR2 C-tail ΔTTL, or CXCR2
C-tail WT) or delivered with CXCR2 C-tail peptides (WT or ΔTTL)
for 24 to 48 hours before the MTT assay.
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Invasion Assay
PDAC cells were plated at a density of 1.5 × 105 cells per well in
24-well plate. Cells were transfected with various pTriEx4 plasmids
(vector alone, CXCR2 C-tail ΔTTL, or CXCR2 C-tail WT). After a
48-hour incubation, in vitro invasion assay was performed using
Transwell inserts with 8.0-μm pore size. Briefly, 1 × 105 transfected
PDAC cells were suspended in serum-free medium and seeded onto
the Transwell inserts pre-coated with diluted (1:3) Matrigel. The
Transwell inserts were then placed into 24-well plates filled with
the same medium containing 100 ng/ml CXCL8. After a 16-hour
incubation, the upper surface of the Transwell inserts was wiped
with a cotton swab and the invaded cells were fixed and stained with
Diff-Quick stain (IMEB, San Marcos, CA). The number of invading
cells was counted under an inverted microscope (×50) in three ran-
domly selected fields per well. In separate experiments, PDAC cells
were delivered with CXCR2 C-tail peptides (WT or ΔTTL) for
24 hours, and the cell invasion was assessed as described above.
Human PDAC Xenografts in Immunodeficient Mice
Three green fluorescent protein (GFP)-tagged adeno-associated virus
type 2 (AAV2) constructs, AAV2/2CMV-GFP, AAV2/2CMV–GFP–
CXCR2 C-tail ΔTTL, and AAV2/2CMV–GFP–CXCR2 C-tail WT
(customized by the Gene Transfer Vector Core, University of Iowa),
were used to transduce HPAC cells. CB17 severe combined immuno-
deficient (CB17-SCID) mice (female, 4–6 weeks old) were randomly
divided into four groups (n = 10–12), and each mouse received 200 μl
of serum-free Dulbecco’s modified Eagle’s medium containing 3 × 106
HPAC cells (transduced or non-transduced) subcutaneously in the
unilateral flank area. The mice were subjected to measurement of
subcutaneous tumors every other day and monitored for changes
in body weight and other side effects. Tumor volume was calculated
by the formula (L × W 2)/2, where L and W are the tumor length
and width (in mm), respectively. To avoid severe discomfort in the
control group, animals were killed after 4 weeks. Tumor tissues were
harvested for histologic analysis and immunohistochemical staining.
Tumor volume in SCID mice was plotted against time, and the final
tumor weights were measured after the mice were killed. All the
animal studies were accomplished under the protocol approved by
Wayne State University Institutional Animal Care and Use Committee.
Ki-67 Proliferation Index
Tumor tissue from the xenografts was fixed by paraformaldehyde
and embedded within paraffin. Paraformaldehyde-fixed and paraffin-
embedded sections (5 μm) were stained with Ki-67 antibody (Ventana
Medical Systems, Tucson, AZ) as reported [33]. Results were expressed
as percentage of Ki-67–positive cells per 200× magnification. A total of
10 sections from each experimental group were examined by Zeiss
Axiophot epifluorescence microscope (Carl Zeiss AG, Oberkochen,
Germany) and analyzed by Image-Pro Plus 6.0 software (Media Cyber-
netics, Berkshire, United Kingdom).
Statistical Analysis
Data are presented as means ± SEM of at least three independent
experiments. Statistical significance of differences was assessed with the
Student’s t test. A value of P < .05 was considered statistically significant.
Figure 1. CXCR2 is overexpressed in human pancreatic cancer
cells. Expression levels of CXCR2 in normal HPDE cells and several
PDAC cell lines (HPAC, Colo357, L3.6pl, PANC-1, and MIA PaCa-2)
were examined by Western blot analysis. Blot analysis of GAPDH
was used as internal control.
Figure 2. CXCR2 and PLC-β3 in PDAC cells preferentially interact
with NHERF1. (A) Endogenous CXCR2 (from indicated PDAC cells)
was pulled down by PDZ scaffold protein (NHERF1, NHERF2, or
PDZK1). The membrane was blotted with anti-CXCR2 antibody.
(B) Endogenous PLC-β3 (from indicated PDAC cells) was pulled
down by PDZ scaffold protein (NHERF1, NHERF2, or PDZK1).
The membrane was blotted with anti–PLC-β3 antibody. (C) Endog-
enous PLC-β3 was pulled down by NHERF1 in a dose-dependent
manner. (D) Pairwise binding between GST-NHERF1 and His-S–
tagged PLC-β3 C-tails (containing the last 100 amino acids) WT,
PDZ motif deletion (ΔTQL), or PDZ motif mutant (AAA). The com-
plex was pulled down by S-protein agarose and immunoblotted
with anti-NHERF1 antibody.
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Results
CXCR2 Is Overexpressed in PDAC Cells
The expression of CXCR2 in normal HPDE cells and several
PDAC cell lines (HPAC, Colo357, L3.6pl, PANC-1, and MIA
PaCa-2) was examined and compared by Western blot analysis.
All the five PDAC cell lines tested in our study showed significantly
increased CXCR2 expression compared to HPDE cells (Figure 1),
which is in agreement with the previous clinical study that reported
an up-regulation of interleukin-8 (IL-8)/CXCL8 and its receptors in
both pancreatic adenocarcinomas and neuroendocrine tumors [10].
CXCR2 and PLC-β3 in PDAC Cells Preferentially Interact
with NHERF1
In a recent study, we demonstrated that the consensus PDZmotif at
the carboxyl terminus of CXCR2 mediates PDZ-based interactions
with certain PDZ scaffold proteins (such as NHERF1 and NHERF2)
in neutrophils [30]. To investigate if endogenous CXCR2 in PDAC
cells binds to any PDZ scaffold proteins, we performed a pull-down assay
[30] as described in Materials and Methods section. As shown in Fig-
ure 2A, we observed interactions between CXCR2 and the membrane-
associated PDZ proteins NHERF1 and NHERF2 in Colo357, L3.6pl,
and HPAC cells, among which NHERF1 has a higher binding affinity
for CXCR2 as compared with NHERF2. However, neither GST nor
PDZK1 was found to bind to endogenous CXCR2 in these PDAC cell
lines (Figure 2A).
CXCR2 couples to the pertussis toxin–sensitive Gi to stimulate
phosphatidylinositide-specific PLC activities [17]. Similar to CXCR2,
all human PLC-β isoforms possess consensus class I PDZ motifs at
their carboxyl termini [29]. Our previous study has demonstrated that
PLC-β3 (containing a PDZ motif -TQL-COOH) overexpressed in
HEK293 cells interact with NHERF1 and NHERF2 [30]. Here, we
explored the potential interactions between PDZ scaffold proteins
(NHERF1, NHERF2, and PDZK1) and endogenous PLC-β3 in
PDAC cell lines. By similar GST pull-down experiments, we observed
that endogenous PLC-β3 in PDAC cells bind to both NHERF1 and
NHERF2; however, it did not bind to PDZK1 or to GST alone
(Figure 2B). Moreover, in comparison to NHERF2, NHERF1 appears
to interact with PLC-β3 with a higher affinity in most of the PDAC cell
lines we tested (Figure 2B). In addition, the binding between endoge-
nous PLC-β3 in PDAC cells and NHERF1 increased with increasing
amounts of NHERF1 in a dose-dependent manner (Figure 2C ).
PLC-β3 Interacts with NHERF1 in a Direct and
PDZ Motif–Dependent Manner
The data from the GST pull-down studies (Figure 2B) does not
reveal that whether the interaction between PLC-β3 and NHERF1 is
direct, since there exists a possibility that PLC-β3 might bind
NHERF1 through other intermediary proteins in the cell lysates. We
performed a pairwise binding assay [30] that detects a direct interaction
between PLC-β3 and NHERF1 in vitro. We observed that PLC-β3
C-tail (containing the PDZ motif) directly binds to NHERF1 in a
Figure 3. NHERF1 clusters CXCR2 and PLC-β3 into a macromolecular complex in vitro and in PDAC cells. (A) Pictorial representation of
in vitro macromolecular complex assembly (refer to Materials and Methods section for details). (B) In vitro macromolecular complex
assembly of CXCR2 C-tails (WT, ΔTTL, and AAA), GST-NHERF1, and endogenous PLC-β3 (from Colo357 and HPAC cells). (C) Endogenous
PLC-β3 and NHERF1 were co-immunoprecipitated with CXCR2 from Colo357 and HPAC cells. (D) Endogenous CXCR2 and NHERF1 were
co-precipitated with PLC-β3 from Colo357 and HPAC cells.
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Figure 4. Disrupting the CXCR2 macromolecular complex inhibits PDAC cell proliferation. (A) HPAC, (B) Colo357, and (C) HPDE cell pro-
liferation in response of CXCL1/CXCL5/CXCL8 (100 ng/ml) was assessed and quantified by MTT assay and expressed as relative to the
initial time point (0 hour). Cell proliferation in response to indicated chemokines (CXCL5 or CXCL8; 100 ng/ml) in Colo357 and HPAC cells,
which were transfected with plasmids expressing CXCR2 C-tail WT or ΔTTL (D, E) or pre-delivered with CXCR2 C-tail–specific peptide WT
or ΔTTL (F, G). (H) Pairwise binding between GST-NHERF1 and various biotin-conjugated CXCR2 C-tail–specific peptide (containing last
13 amino acids) WT, ΔTTL, or AAA. The complex was pulled down by streptavidin agarose and immunoblotted with anti-NHERF1 antibody.
Columns/dots, means of quintuplicates; bars, SEM; *P < .05. NT, cells not transfected or pre-delivered with peptides.
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PDZ motif–dependent manner, as the interaction between NHERF1
and PLC-β3 C-tail lacking the PDZ motif (ΔTQL) or PLC-β3 C-tail
with PDZ motif mutation (AAA) was almost completely abolished
compared to wild-type (WT) PLC-β3 C-tail (Figure 2D).
NHERF1 Clusters CXCR2 and PLC-β3 into a
Macromolecular Complex In Vitro and in PDAC Cells
Results from the above GST pull-down experiments demonstrated
that both endogenous CXCR2 and PLC-β3 in PDAC cells preferen-
tially interact with NHERF1 (Figure 2, A and B), and PLC-β3 binds to
NHERF1 in a direct and PDZ motif–dependent manner (Figure 2D),
similar to the interaction between CXCR2 and NHERF1 as we pre-
viously reported [30]. Hence, we hypothesized that NHERF1 might
nucleate CXCR2 and PLC-β3 forming a macromolecular complex in
a PDZmotif–dependent manner and this complex might be critical for
efficient and specific signaling mediated by CXC chemokine/CXCR2
biologic axis in PDAC cells. Toward this end, we sought to determine if
we could detect a macromolecular complex containing CXCR2,
NHERF1, and PLC-β3 in vitro. Using an in vitro macromolecular
complex assembly assay (Figure 3A) [30], we observed the existence
of a complex composed of CXCR2 C-tail, NHERF1, and endogenous
PLC-β3 in PDAC cells (Figure 3B). Furthermore, we demonstrated
that CXCR2 C-tail did not bind to PLC-β3 directly, and the macro-
molecular complex was not formed by CXCR2 C-tail PDZ motif
mutants (ΔTTL or AAA), indicating that the formation of the CXCR2
macromolecular complex is PDZ motif–dependent (Figure 3B). In
addition, we detected a similar complex consisting of PLC-β3 C-tail
(containing the PDZ motif TQL), NHERF1, and endogenous
CXCR2 from PDAC cells (data not shown).
Results from the above demonstrated that a CXCR2 macromolec-
ular complex exists in vitro; however, it did not provide the evidence
whether this complex exists in native membranes of PDAC cells that
endogenously express all the relevant interacting proteins. To address
this issue, co-IP was performed using either anti-CXCR2 or anti–
PLC-β3 antibodies as described in Materials and Methods section.
We observed that NHERF1 and PLC-β3 in PDAC cells were co-
immunoprecipitated with CXCR2 (Figure 3C ). Similarly, CXCR2
and NHERF1 were also co-precipitated with PLC-β3 from PDAC
cells (Figure 3D), indicating that there is likely to be a macromolecular
complex composed of endogenous CXCR2, NHERF1, and PLC-β3
on the surface membranes of PDAC cells.
CXC Chemokine/CXCR2 Biologic Axis Promotes
PDAC Cell Proliferation
To examine the effect of CXCR2 signaling on PDAC cell prolif-
eration, PDAC cells were treated with CXCR2 ligands followed by
the MTT cell proliferation assay. As illustrated in Figure 4A, HPAC
cells showed significantly elevated cell proliferative activities in re-
sponse to both CXCL8 and CXCL1 (P < .05), and CXCL5 also pro-
moted HPAC proliferation, though without statistical significance
(P = .07). Proliferation of Colo357 cells was significantly augmented
by CXCL5 (P < .05) and also by CXCL8 and CXCL1 though with-
out statistical significance (P = .09 and .2, respectively; Figure 4B). It
has been reported that Colo357 cells showed a significant high level
of CXCL5 secretion [34], underpinning the autocrine effects of
CXCL5 on Colo357 cell proliferation. However, the normal pancre-
atic duct HPDE cells did not demonstrate significantly increased
growth stimulated by the treatment of either of these CXCR2 ligands
(CXCL1, CXCL5, or CXCL8; Figure 4C ).
Disrupting the CXCR2 Macromolecular Complex Inhibits
PDAC Cell Proliferation
Since the CXC chemokine/CXCR2 biologic axis plays an impor-
tant role in PDAC cell proliferation (growth; Figure 4, A and B), and
here we also demonstrated that the PDZ motif of CXCR2 is essential
for the physical coupling of CXCR2 to PLC-β3 mediated by NHERF1
into a macromolecular signaling complex (Figure 3B), therefore, it is
possible that perturbation of the CXCR2 macromolecular complex
might affect CXCR2 ligand–induced PDAC cell proliferation. In a
recent study, we used a CXCR2 C-tail peptide (containing the PDZ
motif ) to disrupt the CXCR2 PDZ motif–mediated interaction with
NHERF1 and observed a functional inhibition of CXCR2 ligand–
induced cell migration in neutrophils [30]. We went on to evaluate
the functional significance of this CXCR2 macromolecular complex in
the CXCR2 ligand–induced PDAC cell proliferation. We transfected
HPAC and Colo357 cells with plasmids encoding CXCR2 C-tail
(WT or PDZ deletion ΔTTL) and evaluated cell proliferative activities.
As shown in Figure 4D, in response to CXCL5, Colo357 transfected
with plasmid containing CXCR2 C-tail WT showed significantly
reduced proliferative activities compared to cells transfected with the
vector alone or CXCR2 C-tail ΔTTL, suggesting that disrupting
CXCR2 macromolecular complex inhibits CXCR2 ligand–induced
Colo357 growth and PDZ motif of CXCR2 is important for PDAC
cell proliferation.HPAC transfectedwithCXCR2C-tailWT showed sig-
nificantly decreased cell proliferation in response to CXCL8 (Figure 4E).
In addition, we delivered the CXCR2 C-tail peptides (WT and ΔTTL)
used in our previous studies [30] toColo357 andHPACcells, andwe also
observed significantly reduced cell proliferation stimulated by CXCL5
(Figure 4F) and CXCL8 (Figure 4G). Furthermore, using the pairwise
binding assay, we also demonstrated that the CXCR2 C-tail peptide
Figure 5. Gene delivery of CXCR2 C-tail sequence significantly
inhibits malignant invasion of pancreatic cancer cell. HPAC cells
were transfected with pTriEx4 vector alone, pTriEx4 CXCR2 C-tail
PDZ motif deletion (ΔTTL), or pTriEx4 CXCR2 C-tail WT. Invasion
through the Transwells pre-coated with Matrigel of transfected
HPAC cells was initiated by CXCL8 (100 ng/ml) and quantified by
microscopy. Columns, means of triplicates; bars, SEM; **P < .01.
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interacts withNHERF1 in a direct and PDZmotif–dependentmanner,
because the CXCR2 WT peptide interacts with NHERF1, while the
PDZdeletion peptide (ΔTTL) ormutation peptide (AAA) failed to bind
to NHERF1 (Figure 4H).
Disrupting the CXCR2 Macromolecular Complex Blocks
PDAC Cell Invasion
We then examined the effect of disrupting CXCR2 signaling com-
plex on the invasive capability of PDAC cells. PDAC cells were trans-
fected with plasmids encoding CXCR2 C-tail (WT or ΔTTL) and used
to evaluate the invasive potency by an in vitro invasion assay as reported
before [34]. As illustrated in Figure 5, gene delivery of CXCR2 C-tail
WT sequence, but not the ΔTTL PDZ deletion sequence, significantly
inhibited invasion of HPAC cells through Matrigel induced by
CXCL8, implicating that the PDZ motif of CXCR2 is important for
PDAC cell invasion.
Disrupting the CXCR2 Macromolecular Complex Inhibits
Pancreatic Tumor Growth In Vivo
To analyze the functional significance of the CXCR2 macromolec-
ular complex in PDAC growth in vivo, a subcutaneous xenograft
induced by HPAC cells in CB17-SCID mice was developed to deter-
mine whether disrupting the CXCR2 signaling complex could lead to
inhibition of tumor growth in vivo. HPAC cells that were transduced
with AAV2 viruses expressing GFP–human CXCR2 C-tails (WT or
ΔTTL) or GFP alone, or non-transduced cells, were injected sub-
cutaneously into CB17-SCID mice. Tumor volume was measured
every other day starting at day 12. At day 28, all mice were sacrificed,
and tumors were excised and final tumor weights were determined.
We found that HPAC cells expressing GFP alone or GFP–CXCR2
C-tail ΔTTL grew into sizable tumors underneath the skin that were
comparable to non-transduced cells (Figure 6A). However, HPAC cells
expressing GFP–CXCR2 C-tail WT grew into significantly smaller
tumors compared with the cancer cells expressing GFP vector alone
Figure 6. Gene delivery of CXCR2 C-tail sequence inhibits PDAC tumor growth in vivo. Tumor volume (A) was measured according to the
formula (1/2 × L × W 2) every other day; and final tumor weights (B) were measured, averaged, and compared after 4 weeks. Prolifer-
ation index (D) was expressed as percentages of Ki-67+ cells (see details in Materials and Methods section); and representative Ki-67+
immunohistochemical images (200×) are shown in (C). *P < .05; **P < .01. NT, non-transduced cells.
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or GFP–CXCR2 C-tail ΔTTL or non-transduced cells (Figure 6A).
Furthermore, transduction with GFP–CXCR2 C-tail WT significantly
reduced final tumor weight compared to the three other groups
(Figure 6B). This result suggests an inhibitory effect of exogenous
CXCR2 C-tail (containing the PDZ motif) on human pancreatic
tumor development and progression in vivo. We then demonstrated
that the proliferation index, determined by Ki-67 expression, in the
group of mice injected with HPAC cells expressing GFP–CXCR2
C-tail WTwas significantly lower (P < .01) compared to the three other
groups (non-transduction group, AAV2-GFP group, and AAV2–GFP–
CXCR2 C-tail ΔTTL group; Figure 6, C and D). Collectively, our
date indicates the potential therapeutic effect of disrupting the CXCR2
macromolecular complex on the primary tumor of PDAC in vivo.
Discussion
CXC chemokines (such as GRO-α/CXCL1, IL-8/CXCL8, ENA-78/
CXCL5) and their cognate receptor CXCR2 have been reported to
play a critical role in tumor growth and angiogenesis, as blockade of
the CXC chemokines/CXCR2 biologic axis reduced tumorigenesis
and angiogenesis in many human cancers including pancreatic cancer
[16,34–36]. However, most of the interventional approaches have
been conducted by systemic blockade or depletion of CXCR2 and/
or its ligands, which might cause global undesired effects on other
vital functions, as CXCR2 had also been reported in many cellular
functions, such as in preservation of oligodendrocyte function and
myelinization of neural tissues [37]. This issue warrants the necessity
of a more comprehensive understanding of the molecular mecha-
nisms of CXCR2 and its signaling, on the basis of which, selective
and cell-specific therapeutic targets could be identified.
CXCR2 possesses a consensus PDZmotif at their carboxyl termini,
and the PDZmotif has been reported to modulate cellular chemotaxis
[31]. Recently, we demonstrated that the PDZ motif of CXCR2 plays
an important role in regulating neutrophil functions as disrupting
the interaction mediated by PDZ motif through using an exogenous
peptide mimic (mapping CXCR2 PDZ motif) significantly inhib-
ited CXCR2-mediated calcium mobilization and neutrophilic trans-
epithelial migration [30]. In the present study, we identified the PDZ
scaffold protein NHERF1 as an interacting partner for CXCR2 in
PDAC cells, and we also demonstrated the existence of a PDZ-based
CXCR2 macromolecular signaling complex containing endogenous
CXCR2, NHERF1, and PLC-β3 in PDAC cells. Furthermore, we
provided functional evidence showing that disrupting the CXCR2
complex significantly inhibited the malignant cellular functions (i.e.,
proliferation and invasion) in vitro and pancreatic tumor growth
in vivo.
Controversy exists regarding the expression of CXCR2 in human
pancreatic cancer cell lines. Despite some studies reported that CXCR2
was not detected in some human PDAC cell lines (such as PANC-1,
MIA PaCa-2, AsPC-1, BxPC-3, and HPAF-II) [33,34,38], other
groups reported the detection of CXCR2 and/or the autocrine effect
of CXCR2 ligands in various human PDAC cells (such as PANC-1,
MIA PaCa-2, Capan-1, Capan-2, SUIT-2, HuP-T4, Bx-PC-3, and
Panc03.27) [11–15,39] and pancreatic tumors specimens from patients
[10,16]. In the present study, we also detected the expression of
CXCR2 in PANC-1, MIA PaCa-2, HPAC, Colo357, and L3.6pl
cells in Western blot analysis (Figure 1) by using the same antibody
Frick et al. used to detect the CXCR2 expression in patient specimens
[16]. Reverse transcription–polymerase chain reaction results from our
study also confirmed the expression of CXCR2 in these cell lines (data
not shown). One possible reason for the failure of some groups to de-
tect CXCR2 in PDAC cell lines might be that expression level of
CXCR2 varies in different conditions. Hussain et al. reported that
the expression level of CXCR2 correlates with tumor grade and stage
in pancreatic adenocarcinomas [10]. Yamamoto et al. also reported that
CXCR2 is upregulated in an orthotopic colon cancer model compared
to the subcutaneous model [40].
PLC-β is the major isozyme that has been well studied to partic-
ipate in GPCR-mediated signaling and modulate the physiological
responses, such as promoting cell growth in cancer [41–43]. Each
PLC-β subtype has its distinct expression pattern and physiological
relevance [41]. Among the four subtypes of PLC-β, PLC-β3 is
expressed in a wide range of cells and tissues [43] and exhibits the
highest affinity to Gβγ subunits and subsequent activation by Gβγ
subunits [44]. A growing body of evidence suggests that PDZ scaffold
proteins are involved in the modulation of PLC-β isoforms in the PDZ
motif–dependentmanner. PLC-β3, with its PDZmotif (-STQL-COOH),
was reported to bind to PDZ domains of NHERF2 and Shank2
through its PDZ motif at its carboxyl termini, in mouse small intestine
[28] and in the postsynaptic density region in neuronal cells [25],
respectively. It has also been shown that PLC-β3 was downregulated
in jejuna villus cells in NHERF1-knockout mice [27]. Results from
our present study revealed that PLC-β3 preferentially binds toNHERF1
in PDAC cells in a direct and PDZmotif–dependent pattern. Therefore,
the specificity and diversity of agonist-induced PLC-β activity and its
downstream signaling may be regulated by the specific interactions of
PLC-β isoforms and certain PDZ scaffold proteins.
There is accumulating evidence suggesting that the formation of
particular macromolecular signaling complexes beneath the plasma
membrane enables the membrane receptors to transduce signals into
cell interior and thereafter influence cell behavior with higher speci-
ficity and efficiency [20–23,30,45]. Our present study revealed a
PDZ motif–dependent CXCR2 macromolecular signaling complex,
in which CXCR2 and PLC-β3 were bridged by NHERF1, in the
PDAC cells. We also demonstrated the functional importance of the
CXCR2 complex in pancreatic cancer cell functions in vitro and in vivo,
as disturbing the CXCR2 complex by using an exogenous CXCR2
C-tail sequence (containing the PDZ motif ) significantly attenuated
malignant cell proliferation and cell invasion of PDAC cells and
tumor growth in vivo. By investigating a network of protein com-
plexes rather than CXCR2 alone in pancreatic cancer, our results
reveal a novel molecular target for the development of specific thera-
peutic strategies and agents that could combat pancreatic cancer.
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